PR Newswire: news distribution, targeting and monitoring
2014

iCo Therapeutics Receives FDA Clearance to Initiate Clinical Trial in Diabetic Macular Edema

Share with Twitter Share with LinkedIn
    VANCOUVER, Jan. 22 /PRNewswire/ - iCo Therapeutics Inc. announced today
 that the United States Food and Drug Administration (FDA) has accepted the
 Investigational New Drug (IND) application for iCo-007 to treat diabetic
 macular edema.
     "The success of our IND application brings iCo one step closer to
 creating an effective treatment for diabetic macular edema," stated Andrew
 Rae, President and CEO of iCo Therapeutics. "We look forward to initiating
 our Phase I clinical trial for diffuse diabetic macular edema in the first
 half of this year."
     Designed and discovered by Isis Pharmaceuticals Inc., iCo-007 is a
 second-generation antisense drug that targets c-Raf kinase messenger RNA.
 iCo-007 is expected to decrease the edema in the retina by decreasing the
 signaling of various growth factors such as VEGF that signal through the
 c-raf kinase / MAP kinase pathway. iCo Therapeutics licensed the product in
 August 2005.
     Diabetic Macular Edema
     About 45% of diabetics will suffer from diabetic retinopathy - a
 condition resulting from changes in the blood vessels in the eye. Diabetic
 macular edema is a swelling of the small area in the centre of the retina
 and causes difficulty in seeing fine details clearly. The swelling is
 caused by fluid leaking from abnormal or fragile blood vessels and can
 result in conditions from mild vision loss to blindness.
     iCo Therapeutics Inc. is an emerging, Vancouver-based biotechnology
 company focused on developing pre-existing drugs for a range of new
 conditions affecting isolated biological environments - areas such as the
 eye, spinal cord, or joints - where locally-administered application of
 these therapies would have minimal systemic distribution and fewer safety
 issues.
     For more information, visit the company website at:
     www.icotherapeutics.com
     CONTACT: Business Development Contact: Dr. John Clement, CT&DO, (778)
 688-0644; Finance,Investor Contact: Mr. John Meekison, CFO, (604) 602-9414;
 Media Contact: Amanda Smith, Principal, Smith Biotech, (778) 846-4116
 
 

SOURCE iCo Therapeutics Inc.

Featured Video

Journalists and Bloggers

Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.

View and download archived video content distributed by MultiVu on The Digital Center.

Share with Twitter Share with LinkedIn
 

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

 
 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

 
 

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.

 

Online Member Center

Not a Member?
Click Here to Join
Login
Search News Releases
Advanced Search
Search
  1. PR Newswire Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
  5. Send a News Release